Pyxis Oncology, Inc. financials

PYXS CIK 0001782223

Source: EDGAR filings · Built 2026-06-02T03:53:34Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Free Cash Flow -63.51M -57.91M -77.44M -95.73M -35.87M -11.57M
EBITDA -79.91M -86.48M -80.27M -122.77M -69.07M -12.43M
Working Capital 50.97M 114.76M 98.84M 154.98M 259.96M 4.41M
Net Debt 3.25M 727.00K 11.67M -160.37M -274.57M -7.30M
Gross Margin 82.77% 97.06%
Operating Margin -609.18% -554.07%
Net Margin -574.55% -478.95%
Return on Equity (ROE) -149.08% -64.04% -58.70% -75.06% -29.07% 81.99%
Return on Assets (ROA) -87.00% -49.20% -42.47% -57.11% -27.13% -126.37%
Current Ratio 3.41× 7.49× 4.84× 5.90× 14.90× 2.20×
Debt-to-Equity 0.35× 0.17× 0.17× 0.12× 0.00× -0.05×
Effective Tax Rate -1.77% 2.72%
Cash Conversion Ratio 0.80× 0.75× 0.96× 0.74× 0.47× 0.79×
Accruals Ratio -0.18× -0.13× -0.02× -0.15× -0.15× -0.27×
SBC % of Revenue 85.16% 80.17%
CapEx Coverage -7055.78× -243.34× -10.51× -13.96× -65.42× -6.80×
Free Cash Flow Per Share $-1.02 $-0.99 $-1.94 $-2.90 $-4.22 $-11.22

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
P/S 5.20× 5.79×
P/B 1.35× 0.77× 0.64× 0.29× 1.35×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Revenues 13.86M 16.15M
Cost of Revenue 2.39M 475.00K
Research and Development Expense 73.70M 58.75M 49.59M 86.13M 51.05M 9.05M
Operating Expenses 82.20M 123.48M 69.72M 12.89M
Operating Income (Loss) -84.42M -89.46M -82.20M -123.48M -69.72M -12.89M
Income Tax Expense (Benefit) 1.39M -2.16M
Net Income (Loss) Attributable to Parent -79.62M -77.33M -73.79M -120.72M -75.97M -12.83M
Earnings Per Share, Basic $-1.28 $-1.32 $-1.85 $-3.65 $-8.95
Weighted Average Number of Shares Outstanding, Basic 62.14M 58.45M 39.90M 33.03M 8.49M
Earnings Per Share, Diluted $-1.28 $-1.32 $-1.85 $-3.65 $-8.95
Weighted Average Number of Shares Outstanding, Diluted 62.14M 58.45M 39.90M 33.03M 8.49M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Cash and Cash Equivalents, at Carrying Value 15.42M 19.47M 9.66M 179.29M 274.74M 8.08M
Assets, Current 72.11M 132.44M 124.60M 186.61M 278.67M 8.10M
Assets 91.52M 157.18M 173.73M 211.38M 280.02M 10.15M
Liabilities, Current 21.13M 17.68M 25.76M 31.63M 18.71M 3.69M
Liabilities 38.11M 36.43M 48.02M 50.55M 18.71M 3.85M
Stockholders' Equity Attributable to Parent 53.41M 120.75M 125.70M 160.82M 261.31M -15.64M
Common Stock, Shares, Outstanding 62.69M 59.97M 44.75M 34.96M 32.22M 1.29M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Net Cash Provided by (Used in) Operating Activities -63.50M -57.67M -70.71M -89.33M -35.33M -10.08M
Payments to Acquire Property, Plant, and Equipment 9.00K 237.00K 6.73M 6.40M 540.00K 1.48M
Net Cash Provided by (Used in) Investing Activities 58.86M 8.15M -104.85M -6.40M -590.00K -1.48M
Net Cash Provided by (Used in) Financing Activities 594.00K 59.33M 5.93M 183.00K 304.04M 35.00K

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (PYXS CIK 0001782223), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

HPP

Hudson Pacific Properties, Inc.

RIOT

RIOT PLATFORMS, INC.

AVPT

AvePoint, Inc.